This story begins our occasional series looking back at the history of oncology since the signing of the National Cancer Act of 1971. The Cancer Letter was founded in 1973.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
